Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.51 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702386 | 0.86 | CHRNA7 (0.52) | CHRNA7PDE5A | |
| SCHEMBL373086 | 0.86 | CHRNA7 (0.58) | CHRNA7 | |
| SCHEMBL4705416 | 0.81 | CHRNA7 (0.53) | CHRNA7CHRNA4SCDSCD5CYP2C9 | |
| SCHEMBL4704002 | 0.81 | CHRNA7 (0.47) | CHRNA7KCNH2SCDSCD5CYP2C9 | |
| SCHEMBL3326108 | 0.80 | CHRNA7 (0.51) | CHRNA7PDE5A | |
| SCHEMBL5416480 | 0.79 | PDE4B (0.51) | CHRNA7 | |
| SCHEMBL4701174 | 0.79 | MKNK1 (0.55) | CHRNA7 | |
| SCHEMBL3326252 | 0.79 | CHRNA7 (0.52) | CHRNA7PDE5A | |
| SCHEMBL3325793 | 0.79 | SCN5A (0.58) | CHRNA7 | |
| SCHEMBL4705145 | 0.78 | CHRNA7 (0.52) | CHRNA7PDE5ACHRNB2CHRNA4SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | CHRNA7 6/4885BRAF 4304/4885KCNH2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.